Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 4.4% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares dropped 4.4% during trading on Wednesday . The company traded as low as $0.37 and last traded at $0.39. Approximately 78,251,078 shares were traded during trading, an increase of 160% from the average daily volume of 30,044,369 shares. The stock had previously closed at $0.40.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Monday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock has a market cap of $72.01 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The stock’s fifty day moving average is $0.21 and its 200-day moving average is $0.41.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.